TGFβ is involved in lowering NK activity by downregulating the expression of natural killer group 2 member D (NKG2D) receptors, which are activation receptors on the surface of NK cells, and downregulated expression of NKG2D receptors is associated with a poor prognosis in patients with cancer [47, 48]. This evidence concerns the gene TGFB1 and cancer.